data shionogi highlight efficaci select
antagonist chronic cough
continu dilig chronic cough landscap discov recent clinic data
shionogi select antagonist develop refractory/
idiopath chronic cough dose use phase ii studi japan specifi
demonstr reduct awak cough frequenc compar
placebo look good compar phase iib data gener merck nyse
gefapix also note incid taste-rel lower competitor
us seem higher observ bellu specul base
posit data shionogi plan initi global dose-find studi chronic
cough near futur
mani unansw question surround asset efficaci demonstr
potenti select antagonist shed light role promin driver
chronic cough regard bellu toronto blu given enhanc select
compar everi antagonist develop result provid addit
support asset significantli reduc cough least amount tast disturb
antagonist clinic develop
background select once-daili receptor antagonist
develop shionogi analges agent neuropath pain antituss agent
refractory/idiopath chronic cough public detail high throughput screen
antagonist compani identifi asset compound select
valu respect unclear
exact molecul expect similar select ratio
compound true shionogi asset would select gefapix
bayer asset select bellu
proof-of-concept studi data meet mid-march shionogi
publish top-lin data placebo-control random crossov phase ii studi japan
assess toler efficaci refractory/idiopath chronic cough
patient design trial shown figur
therapeut dose specifi demonstr reduct awak
cough frequenc primari endpoint merck bayer studi daili cough frequenc
respect compar placebo figur addit
asset shown enhanc patient qol compar placebo verifi statist
signific increas leicest cough questionnair score inform
publish taste-rel lower competitor given
languag interpret less taste-effect gefapix
bellu healthi subject phase trial report tast
disturb project therapeut dose bid
mid begin phase ii studi chronic cough
mid phase ii result chronic cough
year left
short interest float
financi cad
analyst certif disclosur pleas see page
figur studi design proof-of-concept phase ii studi chronic cough
figur reduct awak daili cough frequenc compar placebo phase ii studi
although multipl unknown surround program data compar placebo look good cross-compar
prior result gener gefapix lead antagonist develop reduct awak cough frequenc compar placebo
phase iib studi gefapix shown figur statist signific dose bid howev patient report
form tast alter complet tast loss discontinu treatment result like attribut bind
heterotrim primarili found tast bud gefapix select receptor asset assess
two phase trial bid merck tri identifi optim dose result cough frequenc reduct limit
tast disturb studi expect complet base posit data shionogi plan initi
global dose-find studi refractory/idiopath chronic cough near futur base data pre-clin
data expect also strong effect reduc cough difficult know exactli
compar gefapix without clinic data multipl cough expert consult mention even less effect
gefapix tast advantag would still appeal mani patient
implic data role chronic cough mention lot unansw question surround
phase ii clinic data addit know littl asset pk/pd profil absolut effect tast compani
provid inform dose use proof-of-concept studi cough frequenc record statist analysi use
proport patient respond treatment howev efficaci data demonstr potenti select antagonist
combin literatur bellu preclin data strong reason believ key driver chronic cough
detail inform trial well data studi bayer select antagonist help clarifi
role vs chronic cough note base tast effect observ fact dose
depend increas tast disturb expect bayer asset result higher rate tast disturb
figur reduct awak cough frequenc gefapix compar placebo phase iib studi
refractori chronic cough repres larg market signific unmet need remind host kol call last week
discuss refractori chronic cough variou therapi develop diseas replay call found preval
chronic cough believ popul half refractori current therapi would repres increas
estim patient elig receiv one chronic cough therapi current develop one kol also mention therapi
approv refractori chronic cough awar diseas increas among physician patient popul continu rise
kol call also emphas refractori chronic cough debilit diseas underappreci gener commun
addit fatigu chest pain headach nausea femal patient make total patient popul
experi urinari incontin given lack novel approv therapi last year refractory/idiopath chronic cough remain
signific unmet need outsid non-pharmacolog therapi like speech patholog behavior therapi commonli practic
physician left prescrib sub-optim neuromodul gabapentin pregabalin slow-releas morphin eu
demonstr consist efficaci associ meaning advers event
twelve-month price target base dcf valuat assum wacc termin growth rate million fulli dilut
share pro-forma po potenti upsid model includ better expect clinic result could
requir us boost peak penetr probabl success relev indic expans addit indic
potenti success earlier anticip regulatori approv sale surpass expect patent extens
risk price target includ wors expect clinic result unforeseen competit emerg
initi target indic chang regulatori environ market downturn potenti dilut financ
alpha seri
lifesci capit alpha seri intend encompass high conviction/impact idea within healthcar sector analys
recommend base deep fundament analysi goal help creat alpha investor long run
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect secur subject
compani research analyst cover research view express report accur reflect person view
subject secur subject compani part research analyst compens directli
indirectli relat specif recommend view express research analyst report
